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ABSTRACT 
 
Here  we  report  a  versatile  mammalian  expression  vector  called  pRIGHT11  for  production  of  small 
interfering RNA (siRNA) in cells. This vector uses opposing eukaryotic RNA polymerase III promoters U6 
and H1 to drive the expression of short siRNA. We have demonstrated the effectiveness of pRIGHT11-
generated  siRNA  in  sequence-specific  inhibition  of  transfected  reporter  genes  and  endogenous  genes. 
Furthermore, this retrovirus-based vector can carry a random library of siRNA, and thus can be applied to 
rapid screening of novel genes involved in specific cellular responses. 
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INTRODUCTION 
 
The genomic databases have become available for human 
and a few other model organisms.  In these databases, the 
number of genes of unknown functions has been growing 
exponentially.  The  traditional  genome-wide  methods  for 
analyzing  gene  functions  include  genetic  screens  for 
phenotypic alterations in model organisms. Although these 
methods have been extremely productive in determining 
gene  functions,  they  often  involve  use  of  expensive, 
tedious  and  lengthy  procedures  including  chemical  or 
molecular  mutagenesis,  chromosomal  walking,  and 
introduction of DNA libraries. These limitations hinder the 
use  of  genetic  analysis  to  study  gene  functions  in 
mammalian systems in a high-throughput manner.   
 
Recently, long double stranded RNAs (dsRNA) were used 
for  genome-wide  screens  in  C.  elegans  to  study  its 
developmental processes (Ashrafi et al, 2003; Kamath et 
al,  2003)  and  in  Drosophila  cells  to  dissect  cellular 
pathways  (Kiger  et  al,  2003;  Lum  et  al,  2003).  Since 
dsRNA  triggers  RNA  interference  (RNAi),  these  early 
studies demonstrated the great potential of RNAi to study 
gene function in a genome-wide fashion. RNA-mediated 
interference  (RNAi)  is  a  evolutionarily  conserved 
mechanism for inhibiting expression of specific genes by 
dsRNAs (for recent reviews see Denli and Hannon, 2003; 
Dykxhoorn  et  al,  2003;  Tuschl,  2003;  Voorhoeve  and 
Agami, 2003). However, the dsRNA approach cannot be 
used in mammalian cells, because dsRNA induces a strong 
antiviral  response  resulting  in  cell  death.  Tuschl  and 
colleagues  cleverly  showed  that  21-23  bp  long  small 
interfering RNAs (siRNAs) can elicit RNAi in mammalian 
cells without inducing antiviral responses (Elbashir et al, 
2001).  siRNAs  can  be  introduced  into  cells  as  RNA 
(which  is  either  chemically  synthesized  or  in  vitro 
transcribed)  or  expressed  from  short-hairpin  RNA 
(shRNA)-encoding DNA expression vectors (for a review 
see  Wilson  and  Richardson,  2003).  shRNA  expression 
vectors  often  harbor  an  RNA  polymerase  III  promoter, 
such as H1 or U6 promoter, that drives the expression of a 
shRNA (Brummelkamp et al, 2002; Paddison et al, 2002; 
Sui et al, 2002). Large-scale siRNA screens can be carried 
out in mammalian cells, as a recent effort identified new 
players in death receptor-mediated apoptosis (Aza-Blanc 
et al, 2003).  However, such screens require synthesis of a 
large  number  of  siRNA  in  order  to  cover  the  whole 
genome.    Otherwise,  the  screens  are  biased  toward  the 
selected siRNAs of chosen gene targets.  Ideally, a random 
library of siRNA will serve the purpose for a genome-wide 
screen.   
 
In  this  study,  we  describe  an  siRNA  expression  system 
that uses two polymerase III promoters that are arranged to 
direct the expression of both sense and antisense strands of 
siRNA  in  an  opposite  orientation.  This  system  has  
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considerable  potential  for  the  rapid  identification  of 
functional  genes  in  a  genome-wide  genetic  screen. 
Here we report that this retrovirus-based RNAi vector 
could  efficiently  suppress  the  expression  of  reporter 
and natural genes making it possible to use this system 
as  a  mammalian  genomic  tool  in  genome-wide 
screens. 
 
MATERIALS AND METHODS 
 
Molecular cloning and pRIGHT11 construction 
To construct a retroviral vector for potential genome-wide 
genetic  screen  two  opposing  RNA  polymerase  III 
promoters, i.e., U6 and H1, were used.  H1 promoter was 
obtained  in  a  PCR  using  the  following  primers: 
aaggtcgacccatggaattcgaacgctga (forward) and taggatccga- 
atgctttttagagtggtctcatacagaac (reverse).  U6 promoter was 
amplified from total human genomic DNA by PCR using 
the  following  primers:  aataagcttaacgcgtagtggaaagacgcg- 
caggca  (forward)  and  ttcggatccggaatgctttttttcgtc- 
ctttccacaag (reverse). The H1 PCR product was digested 
with  SalI  and  BamHI,  and  the  U6  PCR  product  was 
digested with HindIII and BamHI.  The two digested DNA 
were  ligated  into  the  HindIII-SalI  sites  of  pLNCX3 
(unpublished), a derivative  of retroviral  vector pLNCX2 
(Clontech). The resulting plasmid is named as pRIGHT11 
(RNA Interference Gene Hacking/Targeting vector) with 
BsmI-BamHI-BsmI sites between the two promoters. The 
restriction  enzyme  BsmI  recognizes  a  nonplalindromic 
sequence  of  GAATGC(1/-1),  and  its  use  keeps  the 
mismatch sequences in the 3’ ends of both promoters to 
only 5 bases (i.e. the AAAAA sequence).  A schematic 
diagram is shown in Figure 1. 
 
To  construct  siRNA-harboring  pRIGHT11,  siRNA-
encoding  oligonucleotides  were  synthesized  and  cloned 
into the BsmI sites (complete digestion of both sites) of 
pRIGHT11,  creating  an  expression  cassette  that 
theoretically produces both sense and anti-sense 21-22 nt 
RNA in cells. 
 
For  making  siRNA  against  luciferase  (siLuc: 
GAGCUGUUUCUGAGGAGCC),  the  following  two 
oligonucleotides were synthesised: AGCTGTTTCTGAGGA- 
GCCt (sense) and GCTCCTCAGAAACAGCTCt (antisense), 
and the annealed oligonucleotides were cloned into the BsmI-
digested pRIGHT11. Similar cloning strategies were used to 
generate  pRIGHT-siGFP  (with  a  siRNA  sequence  of 
GAACGGCAUCAAGGUGAAC,  Arteaga  et  al,  2003), 
pRIGHT-sip53  (with  a  siRNA  sequence  of  GACUCCAG- 
UGGUAAUCUAC,  Brummelkamp  et  al,  2002),  pRIGHT-
siSmad2  (with  a  siRNA  sequence  of  GGAUGA- 
AGUAUGUGUAAAC) and pRIGHT-siSmad3 (with a siRNA 
sequence of GGCCAUCACCACGCAGAAC).  
 
Cell culture, transfection, luciferase and GFP reporter 
assays 
Cell  culture,  transfection  and  functional  assays  were 
carried out as described (Feng et al, 2002; Lin et al, 2003). 
Briefly, HeLa and 293T cells were maintained in DMEM 
supplemented  with  10%  (v/v)  fetal  bovine  serum.  Cells 
were  incubated  at  37
oC  in  a  5%  (v/v)  CO2  incubator. 
Exponentially growing cells at 30-50% confluency were 
transfected  using  LipofectAMINE  following  the 
manufacturer’s instructions (Invitrogen). Forty eight hours 
after transfection, cells were subjected to reporter assays 
or western blotting.  
 
For  luciferase  assay,  plasmid  pGL2, which  contains  the 
luciferase  gene  under  control  of  the  SV40  early  gene 
promoter  (Promega),  was  used  to  measure  luciferase 
production.  Exponentially  grown  HeLa  cells  at  30% 
confluency  were  transfected  with  pGL2,  pSVβgal  (β-
galactosidase expression  plasmid as an internal control), 
and  pRIGHT-siLuc  or  pRIGHT11  control  vector.  The 
amount of transfected DNA was 0.5 µg per well (12-well 
plate).  The  ratio  of  pGL2:pSVβgal:pRIGHT  was  2:1:5.  
Cells were then harvested for measurement of luciferase 
and  β-galactosidase  activities.  All  assays  were  done  in 
duplicate and repeated more than 3 times, and all values 
were  normalized  for  transfection  efficiency  against  β-
galactosidase activity. 
 
For  GFP  assay,  plasmid  pEGFP,  which  contains  the 
enhanced  GFP  under  control  of  CMV  promoter 
(Clontech),  was  transfected,  together  with/without 
pRIGHT-siGFP, into HeLa cells. Forty eight hours after 
transfection,  production  EGFP  was  first  examined  by 
assessing  production  of  green  fluorescence  under  Zeiss 
Axioplan II microscope, and then by western blotting.  In 
western  blotting,  EGFP  was  detected  with  anti-GFP 
antibody  (Santa  Cruz  Biotech)  and  visualized  by 
chemiluminescence (Pierce). 
 
RESULTS AND DISCUSSION 
 
Design  of  pRIGHT11  –  an  RNAi-based  vector  for 
genetic screens 
RNA Polymerase III promoters U6 and H1 have been used 
to drive expression of siRNA (Brummelkamp et al, 2002; 
Paddison et al, 2002; Sui et al, 2002).  Currently there are 
two ways to produce siRNA in cells.  One is to design a 
stem-loop  hairpin  cassette  that  contain  the  following 
structure:  N19(sense  strand)-Loop-N19(antisense  strand) 
(Brummelkamp et al, 2002; Paddison et al, 2002; Sui et al, 
2002).  The RNA product will contain a base-paired stem, 
which  can  be  processed  by  cellular  Dicer  to  become 
double-stranded  ~21-mer  siRNA.    The  other  way  is  to 
express  the  N19  sense  and  the  antisense  in  a  different 
cassette (which  can  be  on  the same  or different  vector) 
(Miyagishi and Taira, 2002).  The individually expressed 
sense N19 and anti-sense N19 will match by base pairing 
in cells.  However, either expression vector cannot be used 
as a vector for efficient library carrier.  Mathematically, a 
random library would be enormously large (4
19+19 = 4
38 = 
~7.6x10
22), impossible for genetic screen.   
 
By  taking  advantage  the  fact  that  nucleotide  sequences 
close to the initiation site of U6 or H1 are not critical for 
promoter specificity and efficiency, we designed a vector 
in such a way that both promoters will be oriented head-to-
head, so that one promoter will drive the expression of the 
sense strand and the other expresses the antisense strand 
(Figure  1).  In  addition,  the  U6  promoter  preferably 
initiates transcription from a G and the H1 promoter also 
prefers G or A, we can further reduce the size of library by  
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using G as the first 5’ nucleotide on both strands.  The 
resulting  random  sequence  will  be  G(N17)C.  Figure  1 
shows schematic presentation of the vector design. 
 
Proof of principle using reporter assays 
To provide proof the principle of our vector design, we 
chose  two  common  reporter  genes,  i.e.,  luciferase  and 
EGFP. The siRNA target sequences for these two reporter 
genes are described in the “Materials and Methods”. By 
cloning corresponding DNA oligonucleotides (that encode 
siRNA) into our vector to replace the G(N17)C region, we 
created pRIGHT-siLuc and pRIGHT-siGFP.   
 
We  next  transfected  293T  cells  with  pGL2  luciferase 
expression  vector  with  or  without  pRIGHT-siLuc,  and 
then measured the luciferase activity in transfected cells.  
We found that pRIGHT-siLuc can effectively knock down 
the  expression  of  the  luciferase  production,  achieving  a 
80%  reduction  in  comparison  to  the  pRIGHT11  vector 
control  (Figure  2A).    In  contrast,  pRIGHT-siGFP  and 
pRIGHT11 vector had no effect.  The effectiveness of the 
pRIGHT-produced  siRNA  was  comparable  to  that  of 
siRNA/shRNA produced by H1-carrying pSUPER vector. 
In  a  similar  experiment  where  we  introduced  GFP 
expression vector together with pRIGHT-siGFP, we found 
that pRIGHT-siGFP can suppress the expression of GFP 
protein.  As shown in Figure 2B, western blotting analysis 
showed  a  dramatic  reduction  of  the  GFP  level  in  the 
presence,  but  not  in  the  absence,  of  pRIGHT-siGFP. 
Furthermore, fluorescence  microscopy  also indicated the
 
 
 
 
 
Figure 1.  Design of pRIGHT11, a retrovirus-based RNAi vector. (A) Schematic presentation of pRIGHT11 and its cloning site 
(CS).  U6 and H1 promoters (big red arrows) are arranged in an opposite orientation. (B) The BsmI-BamHI-BsmI region can be 
replaced by a siRNA-encoding sequence that is identical to a 19-nt region of target mRNA.  Construction of luciferase siRNA in 
pRIGHT11 was used as an example.  BsmI recognition and cut sites are also shown.  
© Lin and Feng | Journal of RNAi and Gene Silencing | August 2005 | Vol 1, No 1 | 38-43 | OPEN ACCESS 
41 
A:              B: 
 
 
 
C: 
 
 
             
 
 
 
Figure 2.  Sequence-specific inhibition of reporter gene expression.  (A) Chemilumiscent analysis of luciferase expression.  HeLa 
cells were transfected with luciferase-expressing vector pGL2 together with/without pRIGHT-siLuc. Luciferase expression was 
determined by chemiluminescence.  Luciferase activity in the empty vector-transfected cells is considered as 100%. siLuc and siGFP 
express siRNA against luciferase and GFP, respectively.  pRIGHT-siLuc and pSUPER-siLuc have similar effects in suppression of 
luciferase expression. (B) Western blotting analysis of GFP expression.  HeLa cells were transfected with pEGFP and the GFP 
protein was analyzed by SDS-PAGE, followed by western blotting using an anti-GFP antibody.  pRIGHT-siGFP expressed siRNA 
against GFP. pRIGHT11 is an empty vector. (C) Microscopic analysis of GFP expression in HeLa cells. GFP was visualized by 
fluorescent light after transfection with pEGFP in the presence of pRIGHT-siGFP or pRIGHT11 vector. 
 
 
suppression of green fluorescence production by pRIGHT-
siGFP, but not by the control vector (Figure 2C).  
 
Silencing of natural gene expression 
We  also  tested  the  usefulness  of  pRIGHT11-produced 
siRNAs  against  a  natural  gene.  For  this  purpose,  we 
constructed pRIGHT-sip53 that expressed p53 siRNA. We 
observed a robust expression of His-tagged p53 in 293T 
cells  after  transfection  with  an  expression  for  His-p53.  
Notably, co-transfection of pRIGHT-sip53 suppressed the 
expression of p53 protein (Figure 3A). 
 
To show that pRIGHT11 vector system can be used for 
knocking  down  the  expression  of  endogenous  genes  in 
mammalian  cells,  we  generated  pRIGHT-siSmad2  that 
expressed  Smad2 siRNA.  We  then  introduced  pRIGHT-
siSmad2 or pRIGHT11 vector into 293T cells (with ~70% 
transfection  efficiency).  Results  show  that  endogenous 
Smad2  expression  could  be  significantly  reduced  by 
increased  pRIGHT-siSmad2,  but  not  by  vector  or 
pRIGHT-siSmad3  (Figure  3B).  In  contrast,  the  level  of 
actin remained unchanged. The results of this experiment 
suggest that pRIGHT11 vector can be used for silencing of 
endogenous genes in mammalian cells. 
 
CONCLUSIONS 
 
In summary, we have designed an expression cassette that 
expresses both sense and antisense strands of siRNA with 
opposing  polymerase  III  promoters  in  mammalian cells.    
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Figure 3. Sequence-specific inhibition of expression of natural 
genes.  A. Inhibition of expression of transfected p53 in 293T 
cells. 293T cells were transfected with p53-His and the p53 
protein was analyzed by SDS-PAGE, followed by western 
blotting using an anti-His antibody.  pRIGHT-sip53 expressed 
siRNA against p53.  pRIGHT-siSmad2 is a non-specific control.   
B. Inhibition of expression of the endogenous Smad2 in HeLa 
cells. 293T cells were transfected with pRIGHT-siSmad2 and the 
Smad2 protein was analyzed by western blotting using an anti-
Smad2 antibody.  pRIGHT-siSmad2 and pRIGHT-siSmad3 
expressed siRNAs against Smad2 and Smad3, respectively.  
 
 
Unlike previously described polymerase III-driven siRNA 
expression  vectors,  pRIGHT11  offers  the  following 
advantages: 
 
1. Economy: The length of DNA oligonucleotides that are 
required for cloning siRNA-encoding DNA is reduced by 
more  than  half.  It  significantly  reduces  the  cost  of 
synthesizing  DNA  oligonucleotides  for  construction  of 
siRNA expression vector (compared to traditional H1 or 
U6 vector).  For making shRNA in a single polymerase 
promoter,  DNA  sequences  of  the  siRNA  targets  are 
arranged as “sense-loop-antisense”.  For example, two 64-
base-long DNA oligonucleotides are needed for making a 
siRNA-encoding sequence into pSUPER (Brummelkamp 
et al, 2002).  In pRIGHT11, the final length of DNA to be 
cloned equals to the length of the siRNA target (i.e. 19-23 
bp).  Yet,  pRIGHT11-mediated  gene  silencing  is  as 
effective as pSUPER. 
 
2. Simplicity: The use of a single enzyme BsmI not only 
further  reduced  the  cost  by  reducing  length  of  DNA 
oligonucleotides  required  for  cloning  but  also  makes 
cloning  easier.  The  annealed  siRNA-encoding  DNA 
oligonucleotides can be cloned into pRIGHT11 in either 
direction. 
 
3.  Versatility:  pRIGHT11  can  be  used  as  a  vector  for 
knocking down expression of known individual genes or 
unknown genes in a genetic screen.  We have proven that 
the pRIGHT vector is useful in knocking down expression 
of transfected reporter genes such as luciferase and GFP, 
and  also  natural  genes  such  as  Smad2  and  p53.  
pRIGHT11 can also be used to create stable cell line that 
express the siRNA of interest by selection of neomycin-
resistant cells. Most importantly, pRIGHT11 is a retroviral 
vector and thus, with high infection efficiency retroviruses 
in  mammalian  cells,  introduction  of  pRIGHT11  siRNA 
library into  mammalian cells can be used to phenotypic 
screen  in  a  genome-wide  manner.    Obviously,  the 
opposing promoter design can be extended to a lentiviral 
vector that is capable of more efficiently infecting primary 
cells ( Rubinson et al, 2003; Scherr et al, 2003; Stewart et 
al, 2003). During the course of our manuscript preparation 
and  review,  two  studies  have  used  similar  opposing 
promoter in a plasmid-based system (Kaykas and Moon, 
2004;  Tran  et  al,  2003).    As  a  retroviral-based  vector, 
pRIGHT11  has  greater  potential  in  its  application  in 
genetic screens.  We have created a retroviral library of 
GN17C  (mathematically  a  size  of  1.7x10
10  siRNA 
molecules)  in  pRIGHT11.  We  are  currently  conducting 
genome-wide  screens  for  genes  involved  in  TGF-β 
signaling,  cell  death,  and  tumor  cell  invasiveness.    We 
anticipate  that  such  screens  will  identify  novel  genes 
involved in the targeted cellular responses. 
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